Unmet needs in the treatment of migraine

The 2017 MAST study was an online survey of adults meeting the International Classification of Headache Disorders (ICHD) version 3 beta criteria for migraine.^{[Lipton et al., 2019]} Out of 15,133 individuals to respond, 3,930 reported currently using acute migraine medication, and were therefore included in the analysis outlined on the slide.^{[Lipton et al., 2019]} Unmet needs were characterised among respondents, showing that the majority of patients – 95.8% (3,765/3,930) – had at least one unmet need.^{[Lipton et al., 2019]} Perhaps unsurprisingly, an increasing number of unmet treatment need domains was associated with worse psychological symptoms, attack-related cutaneous allodynia, and increased migraine symptom severity.^{[Lipton et al., 2019]}

Reference:
Lipton RB, Munjal S, Buse DC, et al. Unmet acute treatment needs from the 2017 migraine in America symptoms and treatment study. Headache 2019; 59 (8): 1310–1323.

Other references used on slide:
Buse DC, Nahas SJ, Schwedt TJ, et al. Unmet treatment needs of people with migraine: results of the CaMEO study. Cephalalgia 2019; 39 (Suppl 1): 184–185, IHC-PO-121.

CGRP Forum. Unmet needs in migraine prevention. https://www.cgrpforum.org/about-cgrp/unmet-needs-in-migraine-prevention. Accessed April 2020.

Lipton RB, Buse DC, Serrano D, et al. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2013; 53 (8): 1300–1311.

Lipton RB. Treatment patterns and unmet needs in the acute treatment of migraine. J Fam Pract 2020; 69 (1 Suppl): S1–S7.